/
ATOS
$2.53+$0.21 (+8.94%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$23.5M
10M shares
52-week range
$1.70 – $19.35
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-44.39
Atossa Therapeutics, Inc. Common Stock
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
www.atossatherapeutics.com- Employees
- 14
- IPO / List date
- Nov 8, 2012
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds ATOS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 109,007 | $573.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-02 | 1-for-15reverse |
| 2018-04-20 | 1-for-12reverse |
| 2016-08-26 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded ATOS yet.
